title: The further evolution of biotech.
abstract: Born 20 years ago with the launch of recombinant insulin, the biotechnology industry is maturing, with several leading companies now rivalling traditional pharmaceutical companies in many ways. What might the next 20 years hold for biotech-based drug development?
authors.affiliation: Decision Resources, Inc., 260 Charles Street, Waltham, Massachusetts 02453, USA.
authors.forename: Tricia
authors.initials: T
authors.lastname: Nagle
authors.forename: Carilee
authors.initials: C
authors.lastname: Berg
authors.forename: Rena
authors.initials: R
authors.lastname: Nassr
authors.forename: Kevin
authors.initials: K
authors.lastname: Pang
mesh_terms: D001709:Biotechnology / Q000191:economics / Q000639:trends*; D002202:Capital Financing; D002986:Clinical Trials as Topic / Q000379:methods; D004345:Drug Industry / Q000191:economics / Q000639:trends*; D005060:Europe; D006801:Humans; D018579:Patient Selection; D014481:United States